Assembly biosciences announces fda fast track designation granted to abi-h2158

Assembly biosciences announces fda fast track designation granted to abi-h2158 for the treatment of chronic hepatitis b virus infection.assembly biosciences - abi-h2158 is being evaluated in an ongoing global phase 2 trial.
ASMB Ratings Summary
ASMB Quant Ranking